Wednesday 20 February 2019 ,
Wednesday 20 February 2019 ,
Latest News
  • Biswa Ijtema ends with Akheri Munajat
  • Scientists decode white shark genome, finding cancer-protective
  • 16 US states sue Trump over emergency wall declaration
  • Two ‘robbers’ killed in Kushtia ‘gunfight’
  • Focus on cybersecurity, privacy, service quality
  • 29.60 acres of Dhaleshwari land allegedly occupied
  • BIWTA resumes eviction of illegal structures on Buriganga banks
  • Rohingyas face cyclone threat
5 February, 2018 00:00 00 AM / LAST MODIFIED: 5 February, 2018 12:39:56 AM

Rivaroxaban Plus Aspirin cuts stroke rate in half

Medscape
Rivaroxaban Plus Aspirin cuts stroke rate in half

Pauline Anderson

Combining the anticoagulant rivaroxaban (Xarelto, Bayer) with aspirin cuts the ischemic stroke rate by almost half without significantly increasing the risk for intracerebral hemorrhage (ICH) compared with aspirin alone in patients with stable atherosclerotic vascular disease, new research shows.

The combination was particularly effective for secondary stroke prevention, researchers report. These new results represent a significant advance in stroke prevention, author Mike Sharma, MD, associate professor of medicine (neurology), McMaster University, Hamilton, Ontario, Canada, told Medscape Medical News.

"What we have seen here is an additional benefit on top of aspirin, which essentially doubles the effect," said Dr Sharma. "If we can increase the effectiveness, have fewer strokes, the better off we'll be."

Updated results of the study — Effect of Rivaroxaban with Aspirin on Stroke Outcomes in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) — were presented here at the International Stroke Conference (ISC) 2018.

Patients with established cardiovascular disease have a high rate of additional events, between 5% and 10%, despite modern preventive therapies, said Dr Sharma. Aspirin has long been

 the standard antithrombotic treatment for prevention.

"We have been stuck with aspirin for decades," but it's only modestly effective for stroke prevention, said Dr Sharma. "If you haven't had an event before, it reduces your risk by about 12%, but even if you have already had a stroke or heart attack, it reduces your risk only by about 19%, so the rest of the risk is untouched."

Rivaroxaban is a selective direct factor Xa inhibitor. It's already approved by the US Food and Drug Administration, indicated (at a dose of 15 mg or 20 mg) for prevention of deep-vein thrombosis in the legs and for prevention of stroke in the setting of atrial fibrillation (AF).

COMPASS enrolled 27,395 patients at 602 centers in 32 countries. Participants had coronary artery disease and could have had a myocardial infarction (MI) within 20 years or multivessel disease, or they had peripheral artery disease (PAD), which included those who had surgery for PAD or intermittent claudication with carotid stenosis (where at least 50% were asymptomatic) and carotid revascularization.

Of the total study population, 1032 patients had previously had a stroke. Patients with AF were excluded from the study.

The trial had three treatment groups: aspirin 100 mg a day, rivaroxaban 5 mg twice daily, and a combination of rivaroxaban 2.5 mg twice daily and aspirin 100 mg per day.

The study was designed to run up to 4 years but was stopped early at 23 months, after an interim analysis uncovered "overwhelming efficacy" of the combination therapy, said Dr Sharma.

Primary results for a composite endpoint of cardiovascular death, stroke, or MI, were published online August 27 in the New England Journal of Medicine and presented at that time at the European Society of Cardiology meeting.

That analysis showed that event rates were 4.1% for the combination therapy and 5.4% for aspirin (hazard ratio [HR] for combination vs aspirin, 0.76; 95% confidence interval [CI], 0.66 - 0.86; P < .0001), but major bleeding events occurred in more patients in the combination group (3.1% vs 1.9%; HR, 1.70; 95% CI, 1.40 - 2.05; P < .001).

Intracranial or fatal bleeding did not significantly differ between these two groups. Rivaroxaban by itself did not show a benefit over aspirin alone.

The current analysis looked specifically at stroke endpoints and found that for the combined stroke outcome (ischemic and hemorrhagic), there was a significant reduction for the combination therapy compared with aspirin alone (HR, 0.58; 95% CI, 0.44 - 0.76; P < .0001). The HR with rivaroxaban alone was 0.82 (95% CI, 0.65 - 1.05; P = .12)

"As you can see from the Kaplan-Meier curves, there is an early and consistent separation of the combination arm of rivaroxaban plus aspirin over aspirin," Dr Sharma said at a media briefing.

"Rivaroxaban alone stays very close to the aspirin arm and separates at about 18 months. We're not sure of the reason for that; it does not show significant benefit."

For ischemic stroke, the risk was cut almost in half for the combination therapy (HR, 0.51), with a "robust early separation of the curves" for the combination therapy over aspirin, said Dr Sharma.

"Once again, rivaroxaban by itself stays very close to the aspirin arm to 18 months or so and then separates."

The analysis showed that the rate of hemorrhagic transformation (bleeding into areas of infarct) was reduced in patients taking the combination therapy compared with those taking aspirin (HR, 0.35; 95% CI, 0.13 - 0.99; P = .04).

"We would expect this to be increased with anticoagulation," commented Dr Sharma.

There was no statistically significant increase in hemorrhagic stroke with the combined approach compared with the aspirin alone (P = .33), However, more hemorrhages occurred with combination than with aspirin therapy (15 vs 10).

"Any time you affect blood coagulation, you're going to get some bleeding," said Dr Sharma. "With all factor Xa inhibitors, there is an increase in bleeding in the [gastrointestinal] tract. In this trial, with the combination therapy, we saw a slight increase in bleeding outside the brain but happily no real increase inside the brain."

The 30-day mortality did not significantly differ between the groups.

As for the chance of being disabled or dead (modified Rankin Scale [mRS] score of 3 to 6) at 7 days or at hospital discharge, the combined therapy again came out on top (HR, 0.58; 95% CI, 0.37 - 0.89; P = .01)

"We think this was due to a reduction in the event rate for strokes altogether," said Dr Sharma. He noted that there was a similar reduction in the hazard of having a stroke with an mRS score of 0 to 2.

The biggest predictor of having any kind of stroke was having had one in the past (2.6% per year; P = .0001). A previous MI did not significantly increase the risk for stroke. Having carotid stenosis, or having undergone previous carotid surgery or stenting, increased the risk for ischemic stroke but not hemorrhagic stroke.

While an estimated 77% of strokes occur in patients who have never had a stroke, the researchers wanted to look at the risk in those with a history of stroke. In this secondary prevention population, those on aspirin had strokes at a rate of 3.4% per year, but among those with combination therapy, the rate was reduced to 0.7% per year (HR, 0.42; 95% CI, 0.19 - 0.92; P = .03).

The absolute risk reduction was 2.7 percentage points per year, and the number needed to treat was 37.

Dr Sharma stressed that this combination approach is not for every patient. "If you've got coronary artery disease, had a previous heart attack, or have peripheral vessel disease or carotid stenosis, then this is absolutely a combination to consider; but if you don't have those, we're not sure it will have the same benefit," he said, adding that this is also true for aspirin alone.

"If you're a 32-year-old healthy man, I don't think there's any benefit," he added.

Commenting on the study for Medscape Medical News, Larry B. Goldstein, MD, Ruth L Works Professor and  chairman, Department of Neurology, University of Kentucky, Lexington, said he found it somewhat challenging to determine the impact of the combination therapy on secondary stroke prevention because patients with a prior stroke made up only a subpopulation.

"These were mostly patients with coronary heart disease, and the study was evaluating a combined outcome: stroke/MI and death together, so that makes it a little difficult to tease that out."

The "big concern," said Dr Goldstein, is that adding any anticoagulant to aspirin will increase the risk for bleeding in those who have had a stroke.

"Almost all these drugs have a narrow potential index between decreasing recurrent ischemic events, decreased blood clots, and causing bleeding."

 

Comments

Most Viewed
Digital Edition
More story
From the Editor

From the Editor

Our cover story this week is on Dental Disorders. Teeth are a very important part of the human body. They are the body's hardest and most durable…
Cancer’s long-term prognosis: As an oncologist I’ve never been so hopeful

Cancer’s long-term prognosis: As an oncologist I’ve never been so hopeful

“You’re an oncologist, isn’t that depressing?” Answering this question, posed with equal parts dread and fascination, is an occupational…
What are the most common dental problems?

What are the most common dental problems?

Tammy Davenport    Dental problems are never any fun, but the good news is that most of them can be easily prevented. Brushing twice a day,…
Tooth, cavities and root canal

Tooth, cavities and root canal

Our dental surgeons now a days talk about re-construction of a broken tooth with a chemical compound they call 'miracle mix' or magic mix'…
What can you do about sensitive teeth?

What can you do about sensitive teeth?

If you pass on hot or cold drinks because you know they’ll make your teeth hurt, it may be time to talk to your dentist about the possibility that…
Everything you need to know about bad breath

Everything you need to know about bad breath

Tim Newman Bad breath affects an estimated 25 percent of people. There are a number of possible causes of halitosis, but the vast majority come down to…
7 Daily ways to protect your teeth

7 Daily ways to protect your teeth

Some say the eyes are the window to the soul. But if you really want to know what someone’s about, check their smile. A welcoming show of pearly…
Surprise rheumatoid arthritis discovery points to new treatment for joint inflammation

Surprise rheumatoid arthritis discovery points to new treatment for joint inflammation

Researchers at the University of Virginia School of Medicine have identified an unexpected contributor to rheumatoid arthritis that may help explain the…
Enhance social emotional learning along with cognitive capacity of the children with NDDs

Enhance social emotional learning along with cognitive capacity of the children with NDDs

Neurodevelopmental disorders (NDDs) are indicated by developmental deficits which usually appear at the early age of a child’s development and can…
icddr,b explores sustainable ways to improve WASH and menstrual hygiene management in RMG factories

icddr,b explores sustainable ways to improve WASH and menstrual hygiene management in RMG factories

icddr,b in partnership with The Waterloo Foundation, UK have undertaken a new study to explore water, sanitation and hygiene (collectively known as WASH)…
Researchers find clues that depression may speed brain aging

Researchers find clues that depression may speed brain aging

Memory and thinking skills naturally slow with age but now scientists are peeking inside living brains to tell if depression might worsen that decline—and…
FDA approves Spravato (esketamine) nasal spray for adults with treatment-resistant depression

FDA approves Spravato (esketamine) nasal spray for adults with treatment-resistant depression

The Janssen Pharmaceutical Companies of Johnson & Johnson recently announced that the U.S. Food and Drug Administration (FDA) Psychopharmacologic…
FDA approves Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP), first generic of advair diskus

FDA approves Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP), first generic of advair diskus

Mylan N.V. recently announced the U.S. Food and Drug Administration (FDA) approval of Wixela Inhub (fluticasone propionate and salmeterol inhalation powder,…

Copyright © All right reserved.

Editor : M. Shamsur Rahman

Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Editor : M. Shamsur Rahman
Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Disclaimer & Privacy Policy
....................................................
About Us
....................................................
Contact Us
....................................................
Advertisement
....................................................
Subscription

Powered by : Frog Hosting